The treatment of anemia in peritoneal dialysis patients

Clinical Nephrology

Volumn 56, Issue 6, 2001, Pages 415-427

  Lacson E , Jr ^a   Diaz Buxo, J A ^a  

^a NONE   (United States)

Author keywords

Anemia; Erythropoietin; Iron supplementation; Peritoneal dialysis

Indexed keywords

ALUMINUM; ANDROGEN; ANTACID AGENT; ASCORBIC ACID; FERRIC HYDROXIDE SUCROSE; FERRLICIT; FERROUS GLUCONATE; HEPARIN; IRON; IRON DEXTRAN; IRON SACCHARATE; OMEPRAZOLE; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL DISCOMFORT; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; BLOOD TRANSFUSION; BRONCHOSPASM; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG FORMULATION; DYSPNEA; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HEMATOCRIT; HEMATOMA; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION PAIN; KIDNEY FAILURE; MYALGIA; PERITONEAL DIALYSIS; PRURITUS; REVIEW; SKIN DISCOLORATION; WHEEZING;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; TRANSFERRIN;

EID: 0035213889     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. A consensus on current issues and controversies in iron management of patients with chronic renal failure
2. The efficiency of fractionated parenteral iron treatment in CAPD patients
3. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy
4. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study
5. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin
6. Adverse effects of intramuscular iron injection
7. Monitoring of iron requirements in renal patients on erythropoietin
8. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia
9. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients
10. Parenteral iron use in the management of anemia in end-stage renal disease patients
11. Intramuscular iron therapy in iron-deficiency anemia
12. Subcutaneous epoietin-β in renal anemia: An open multicenter dose titration study of patients on continuous peritoneal dialysis
13. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients
14. An indistinct balance: The safety and efficacy of parenteral iron therapy
15. A study of parenteral iron regimens in hemodialysis patients
16. Serum sickness from iron-dextran administration
17. Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis
18. Microencapsulated ferrous sulfate to fortify cow milk: Absorption and distribution in mice
19. Do pregnant women take their iron?
20. Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients?
21. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients
22. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin
23. European best practice guidelines for the management of anemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure
24. Rusty peritoneal dialysis fluid after intravenous administration of iron dextran
25. Cellular mechanism of resistance to erythropoietin
26. Maintaining iron balance with total-dose infusion of intravenous iron dextran
27. Disorders of iron metabolism. Diagnostic methods
28. Intravenous iron hydroxysaccharate: Establishing the optimum dose
29. Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients
30. Mortality risks of peritoneal dialysis and hemodialysis
31. Hematocrit levels and associated Medicare expenditures
32. Clinical evaluation of iron deficiency
33. Iron dextran-induced muscle pain
34. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients
35. Peritoneal dialysis adequacy: A model to assess feasibility with various modalities
36. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance
37. Failure of CAPD patients to respond to an oral iron absorption test
38. Indices of iron status in continuous ambulatory peritoneal dialysis patients
39. Modulating factors in the hematopoietic response to erythropoietin
40. Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy
41. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans
42. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: A European dose-response study
43. Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin
44. Iron treatment: Impact of safety issues
45. Review of issues relating to iron and infection
46. The evaluation of iron status in hemodialysis patients
47. The safety of intravenous iron dextran in hemodialysis patients
48. Iron management in end-stage renal disease
49. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients
50. Rhabdomyolysis after intramuscular iron-dextran in malabsorption
51. Pulmonary edema: Atypical anaphylactoid reaction to intravenous iron dextran
52. Acute-phase proteins and other systemic responses to inflammation
53. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration
54. In search of sterile, endotoxin-free dialysate
55. Iron metabolism in haemodialysis patients. A study of the management of iron therapy and overload
56. Inhibition of iron absorption by omeprazole in rat model
57. Sarcoma after intramuscular iron injection
58. Effects of meals and ascorbic acid on the absorption of a therapeutic dose of iron as ferrous and ferrie salts
59. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
60. Search for substances promoting the absorption of iron. Studies on absorption and side effects
61. Intravenous iron dextran in clinical medicine
62. Guide to total dose intravenous iron dextran therapy
63. Ferritinaemia in cancer
64. Safety assessment of iron EDTA (sodium iron (Fe(3+)) ethylenediaminetetraacetic acid): Summary of toxicological, fortification and exposure data
65. Iatrogenic contribution to anaemia of chronic renal failure
66. How to diagnose and correct iron deficiency during rhuEPO therapy - A consensus report
67. A protocol for administering intravenous iron dextran in peritoneal dialysis patients
68. Regulation of iron absorption in iron-loaded subjects with end-stage renal disease: Effects of treatment with recombinant human erythropoietin and reduction of iron stores
69. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
70. Water treatment for hemodialysis
71. Ferritin in serum. Clinical and biochemical implications
72. Clinical use of total-dose infusion of iron dextran
73. Iron-dextran anaphylactic-like reaction after a negative test dose and subsequent successful administration of three doses
74. Subcutaneous compared with intravenous epoietin in patients receiving hemodialysis
75. Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release
76. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients
77. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminum
78. Meta-analysis of efficacy and tolerability data on iron proteinsuccinylate in patients with iron deficiency anemia of different severity
79. In vitro and in vivo studies of erythropoiesis during continuous ambulatory peritoneal dialysis
80. Development and comparison of iron dextran products
81. Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. V. The significance of the coordinated iron component
82. Hematocrit values in the CAPD/CCPD population: A report of the National CAPD Registry
83. Serum ferritin: Does it differ from tissue ferritin?
84. Hemodialysis-associated induction of cytokines
85. Prediction of response to erythropoietin treatment in chronic anemia of cancer
86. Retention of cytokine-inducing substances inside high-flux dialyzers
87. The influence of dialysis treatment modality on the decline of remaining renal function
88. Hematocrit level and associated mortality in hemodialysis patients
89. Optimal iron management in patients receiving erythropoietin therapy
90. Metabolic adjuvants to erythropoietin therapy
91. Strategies for iron supplementation: Oral versus intravenous
92. Detection of functional iron deficiency during erythropoietin treatment: A new approach
93. Pharmacokinetics of novel erythropoiesis-stimulating protein compared with epoietin-α in dialysis patients
94. Clinical pharmacokinetics of epoietin (recombinant human erythropoietin)
95. A randomized controlled study of iron supplementation in patients treated with erythropoietin
96. Sarcoma after injection of intramuscular iron
97. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin
98. Working capacity is increased following recombinant human erythropoietin treatment
99. Total dose iron therapy using iron-dextran by intraperitoneal route
100. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia
101. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond (editorial; comment)
102. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO
103. Predictors of loss of residual renal function among new dialysis patients
104. Iron nutrition and absorption: Dietary factors which impact iron bioavailability
105. Volume stress-induced peritoneal endothelin-1 release in continuous ambulatory peritoneal dialysis
106. Erythropoietin therapy in peritoneal dialysis patients
107. Improvement of iron utilization and anemia in uremic patients switched from hemodialysis to continuous ambulatory peritoneal dialysis
108. The integrity of the stomach as a requirement for maximal iron absorption
109. NFK-DOQI Clinical Practice Guidelines: Treatment of anemia of chronic renal failure
110. Hyporesponsiveness to erythropoietin: Overview, 1996
111. Achieving target hematocrit in dialysis patients: New concepts in iron management
112. Multicenter trial of erythropoietin in patients on peritoneal dialysis
113. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial
114. Iron deficiency in patients with renal failure
115. Hematocrit and residual renal creatinine clearance in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)
116. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis
117. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats
118. Relationship between anemia and adequacy of continuous ambulatory peritoneal dialysis
119. Chronic administration of iron dextran into the peritoneal cavity of rats
120. Sodium ferric gluconate complex given intravenously for iron deficiency in hemodialysis
121. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
122. The absence of toxicity in intraperitoneal iron dextran administration: A functional and histological analysis
123. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: Role of iron deficiency
124. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
125. Serum and intracellular detection of cytokines in patients undergoing chronic hemodialysis
126. Role of transferrin measurement in monitoring iron status during recombinant human erythropoietin therapy
127. Is anaemia during continuous ambulatory peritoneal dialysis really better than during haemodialysis?
128. Iron monitoring and supplementation: How do we achieve the best results?
129. Clinical applications of iron management in peritoneal dialysis patients
130. Intravenous ferric saccharate as an iron supplement in dialysis patients
131. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies
132. Resistance to recombinant human erythropoietin therapy: A real clinical entity?
133. Transferrin oversaturation
134. Iron dextran treatment in peritoneal dialysis patients on erythropoietin
135. Safety of intravenous injection of iron saccharate in haemodialysis patients
136. The dilemma of evaluating iron status in dialysis patients-limitations of available diagnostic procedures
137. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload
138. Oral iron absorption test in patients on CAPD: Comparison of ferrous sulfate and a polysaccharide ferric complex
139. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure
140. Effectiveness of erythropoiesis on supervised intradialytic oral iron and vitamin C therapy is correlated with Kt/V and patient weight
141. Patient selection to peritoneal dialysis versus hemodialysis according to comorbid conditions
142. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial
143. The natural history of iron deficiency in hemodialysis patients with dialysis-associated anemia
144. Iron status in patients receiving erythropoietin for dialysis-associated anemia
145. Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis
146. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin
147. Hematocrit levels and hospitalization risks in hemodialysis patients
148. "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in hemodialysis patients